1. Cell Therapy for Lung Diseases. Report from an NIH–NHLBI Workshop, November 13–14, 2012
- Author
-
Matthay, Michael A, Anversa, Piero, Bhattacharya, Jahar, Burnett, Bruce K, Chapman, Harold A, Hare, Joshua M, Hei, Derek J, Hoffman, Andrew M, Kourembanas, Stella, McKenna, David H, Ortiz, Luis A, Ott, Harald C, Tente, William, Thébaud, Bernard, Trapnell, Bruce C, Weiss, Daniel J, Yuan, Jason X-J, and Blaisdell, Carol J
- Subjects
Rare Diseases ,Cardiovascular ,Cancer ,Heart Disease ,Lung ,Lung Cancer ,Respiratory ,Good Health and Well Being ,Biomedical Research ,Cell- and Tissue-Based Therapy ,Humans ,Lung Diseases ,National Heart ,Lung ,and Blood Institute (U.S.) ,United States ,mesenchymal stromal (stem) cells ,epithelial and endothelial progenitor cells ,lung stem cells ,Medical and Health Sciences ,Respiratory System - Abstract
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health convened the Cell Therapy for Lung Disease Working Group on November 13-14, 2012, to review and formulate recommendations for future research directions. The workshop brought together investigators studying basic mechanisms and the roles of cell therapy in preclinical models of lung injury and pulmonary vascular disease, with clinical trial experts in cell therapy for cardiovascular diseases and experts from the NHLBI Production Assistance for Cell Therapy program. The purpose of the workshop was to discuss the current status of basic investigations in lung cell therapy, to identify some of the scientific gaps in current knowledge regarding the potential roles and mechanisms of cell therapy in the treatment of lung diseases, and to develop recommendations to the NHLBI and the research community on scientific priorities and practical steps that would lead to first-in-human trials of lung cell therapy.
- Published
- 2013